Patients and Caregivers |ImmunoGen ADC Technology-focused Cancer Treatments

Patients And

Caregivers

We want to do our part to keep cancer from disrupting lives – not only by developing targeted cancer therapies, but also by providing access to educational resources that help patients and caregivers on their journey to more good days.

OUR CLINICAL TRIALS

We have a variety of ongoing clinical trials in different therapeutic areas, which are detailed below. If you have any questions about any of these trials, contact our Medical Affairs team via email medicalaffairs@immunogen.com or by phone (+1-781-895-0115).

ACUTE MYELOID LEUKEMIA (AML)

ClinicalTrials.gov Identifier: NCT02674763
Description: Phase 1, Multi-center, Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
Status: Recruiting

ClinicalTrials.gov Identifier: NCT03386513
Description: Phase 1, Multi-center, Open-label Study of IMGN632 in Patients With Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Status: Recruiting

BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

ClinicalTrials.gov Identifier: NCT03386513
Description: Phase 1, Multi-center, Open-label Study of IMGN632 in Patients With Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Status: Recruiting

OVARIAN CANCER

ClinicalTrials.gov Identifier: NCT02631876
Description: Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Status: Active, Not Recruiting

ClinicalTrials.gov Identifier: NCT02606305
Description: Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Status: Recruiting

Understanding ADCs

The concept of an ADC is simple: select a cancer-killing toxin and attach it to a specific antibody using a biodegradable linker. But, what we learned from 38 years of research with hundreds of patients and caregivers was that, while “simple” for scientists, ADCs aren’t necessarily easy to understand for non-scientists. With this insight in mind, we created a simple animation that explains ADCs and how they work.

CAREGIVER RESOURCES

Visit the National Patient Advocate Foundation to learn more about person-centered care
Find out what to expect if you become a caregiver for a person with cancer from the American Cancer Society
Learn more about the services, programs, and resources the Family Caregiver Alliance provides for caregivers

HEMATOLOGIC DISORDERS

Explore acute myeloid leukemia (AML) from the Leukemia and Lymphoma Society
Explore blastic plasmacytoid dendritic cell neoplasm (BPDCN) from the Leukemia and Lymphoma Society
Get to know the Leukemia and Lymphoma Society and the resources they provide

IMMUNOGEN RESOURCES

Learn more about our Expanded Access Policy
Contact our Medical Affairs Team

CLINICAL TRIAL RESOURCES

Visit MedlinePlus.gov to understand how Medical Research works
Learn more about clinical studies on ClinicalTrials.gov
Access clear and simple clinical trial information designed for patients and caregivers at Cancer.gov

OVARIAN CANCER

Watch a video about ovarian cancer information from the National Cancer Institute
Access a variety of easy-to-understand ovarian cancer resources from the National Ovarian Cancer Coalition
Learn more about the largest global organization dedicated to fighting ovarian cancer, the Ovarian Cancer Research Fund Alliance
See how the Clearity Foundation is working to improve treatment options for ovarian cancer patients
Connect to ovarian cancer support programs through Sharsheret
Support World Ovarian Cancer Day through the World Ovarian Cancer Coalition